Prosecution Insights
Last updated: July 17, 2026
Application No. 18/495,182

METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST

Final Rejection §DP
Filed
Oct 26, 2023
Priority
Aug 21, 2012 — provisional 61/691,625 +8 more
Examiner
MERTZ, PREMA MARIA
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Regeneron Pharmaceuticals Inc.
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
543 granted / 760 resolved
+11.4% vs TC avg
Strong +36% interview lift
Without
With
+35.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
44 currently pending
Career history
786
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
39.4%
-0.6% vs TC avg
§102
10.3%
-29.7% vs TC avg
§112
37.2%
-2.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 760 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Amended claims 132, 134, (4/22/2026), and previously presented claim 152-155 are pending and under consideration by the Examiner. Claims 1-131, 133, and 135-151 have been canceled. 3. Receipt of Applicant's arguments and amendments filed on 4/22/2026 is acknowledged. 4. The following previous rejections and objections are withdrawn in light of applicants amendments filed on 4/22/2026: (i) the rejection of claims 132, 134, and 152-155 on the ground of non-statutory double patenting as being unpatentable over claims 1-40 of US Patent No. 11,034,768 (‘768); (ii) the rejection of claims 132, 134, and 152-155 on the ground of non-statutory double patenting as being unpatentable over claims 1-30 of US Patent No. 10,137,193 (‘193). Claim rejections-Double Patenting Non-statutory double patenting rejection (obviousness-type) The non-statutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A non-statutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on non-statutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a non-statutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). 5a. Claims 132, 134, and 152-155 are rejected on the ground of non-statutory double patenting as being unpatentable over claims 1-33 of US Patent No. 11,845,800 (‘800). This rejection is maintained for reasons of record set forth at pages 3-9 of the previous action dated 1/22/2026. 5b. Claims 132, 134, and 152-155 are rejected on the ground of non-statutory double patenting as being unpatentable over claims 1-19 of US Patent No. 9,574,004 (‘004). This rejection is maintained for reasons of record set forth at pages 10-11 of the previous action dated 8/6/2025. Claim rejections-Provisional Double Patenting Provisional Non-statutory double patenting rejection (obviousness-type) 5e. Claims 132, 134, and 152-155 are provisionally rejected on the ground of non-statutory double patenting as being unpatentable over claims 132-159 of co-pending Application No. 19/385,591 (‘591). This is a provisional non-statutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion No claims are allowed. Claims 132, 134, and 152-155 are rejected. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Advisory Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to PREMA MARIA MERTZ whose telephone number is (571)272-0876. The examiner can normally be reached on Monday to Thursday from 7:30am to 6:00pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, VANESSA FORD, can be reached at telephone number 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /PREMA M MERTZ/ Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Oct 26, 2023
Application Filed
Dec 22, 2025
Non-Final Rejection (signed) — §DP
Jan 22, 2026
Non-Final Rejection mailed — §DP
Apr 08, 2026
Interview Requested
Apr 14, 2026
Applicant Interview (Telephonic)
Apr 14, 2026
Examiner Interview Summary
Apr 22, 2026
Response Filed
May 21, 2026
Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678486
CELL IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
3y 11m to grant Granted Jul 14, 2026
Patent 12674136
METHODS FOR PREPARING TUMOR-INFILTRATING LYMPHOCYTES
3y 0m to grant Granted Jul 07, 2026
Patent 12661402
POLYPEPTIDE SPECIFIC FOR MUCIN 1 AND USE THEREOF
3y 0m to grant Granted Jun 23, 2026
Patent 12655209
FcRn Antibodies and Methods of Use Thereof
4y 1m to grant Granted Jun 16, 2026
Patent 12655206
Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody
4y 3m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+35.8%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 760 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month